scispace - formally typeset
Search or ask a question
Institution

Rambam Health Care Campus

HealthcareHaifa, Israel
About: Rambam Health Care Campus is a healthcare organization based out in Haifa, Israel. It is known for research contribution in the topics: Population & Cancer. The organization has 2498 authors who have published 3715 publications receiving 104362 citations. The organization is also known as: Rambam Hospital & Bet ha-ḥolim ha-memshalti Rambam.


Papers
More filters
Journal ArticleDOI
TL;DR: A brief review of major milestones in medical imaging from its inception to date is provided, with a few considerations regarding future directions in this important field.
Abstract: Today medical imaging is an essential component of the entire health-care continuum, from wellness and screening, to early diagnosis, treatment selection, and follow-up. Patient triage in both acute care and chronic disease, imaging-guided interventions, and optimization of treatment planning are now integrated into routine clinical practice in all subspecialties. This paper provides a brief review of major milestones in medical imaging from its inception to date, with a few considerations regarding future directions in this important field.

60 citations

Journal ArticleDOI
TL;DR: Changes in vascular FDG activity and CT calcifications can be assessed by repeat PET/CT, and FDG-avid foci may represent a dynamic process, transient inflammation, whereasCT calcifications may indicate stable atherosclerosis.

59 citations

Journal ArticleDOI
TL;DR: Functional assays revealed that these MORC2 variants result in hyperactivation of epigenetic silencing by the HUSH complex, supporting their pathogenicity and expanding the spectrum of genetic disorders resulting from pathogenic variants in MORC1.
Abstract: MORC2 encodes an ATPase that plays a role in chromatin remodeling, DNA repair, and transcriptional regulation. Heterozygous variants in MORC2 have been reported in individuals with autosomal-dominant Charcot-Marie-Tooth disease type 2Z and spinal muscular atrophy, and the onset of symptoms ranges from infancy to the second decade of life. Here, we present a cohort of 20 individuals referred for exome sequencing who harbor pathogenic variants in the ATPase module of MORC2. Individuals presented with a similar phenotype consisting of developmental delay, intellectual disability, growth retardation, microcephaly, and variable craniofacial dysmorphism. Weakness, hyporeflexia, and electrophysiologic abnormalities suggestive of neuropathy were frequently observed but were not the predominant feature. Five of 18 individuals for whom brain imaging was available had lesions reminiscent of those observed in Leigh syndrome, and five of six individuals who had dilated eye exams had retinal pigmentary abnormalities. Functional assays revealed that these MORC2 variants result in hyperactivation of epigenetic silencing by the HUSH complex, supporting their pathogenicity. The described set of morphological, growth, developmental, and neurological findings and medical concerns expands the spectrum of genetic disorders resulting from pathogenic variants in MORC2.

59 citations

Journal ArticleDOI
28 Aug 2020-Cancers
TL;DR: The first indication of the impact of cannabis consumption during immune checkpoint inhibitors immunotherapy cancer treatment is provided and it is shown that the levels of endogenous serum eCB and eCB-like lipids are affected by immunotherapy and may potentially constitute monitoring targets to cancer immunotherapy treatment, which currently has poor clinical markers for predicting patient response rates.
Abstract: Cannabis or its derivatives are widely used by patients with cancer to help with cancer symptoms and treatment side effects. However, cannabis has potent immunomodulatory properties. To determine if cannabis consumption during immunotherapy affects therapy outcomes, we conducted a prospective observatory study including 102 (68 immunotherapy and 34 immunotherapy plus cannabis) consecutive patients with advanced cancers who initiated immunotherapy. Cannabis consumption correlated with a significant decrease in time to tumor progression and overall survival. On the other hand, the use of cannabis reduced therapy-related immune-related adverse events. We also tested the possibility that cannabis may affect the immune system or the tumor microenvironment through the alteration of the endocannabinoid system. We analyzed a panel of serum endocannabinoids (eCBs) and eCB-like lipids, measuring their levels before and after immunotherapy in both groups. Levels of serum eCBs and eCB-like lipids, before immunotherapy, showed no significant differences between cannabis users to nonusers. Nevertheless, the levels of four eCB and eCB-like compounds were associated with patients’ overall survival time. Collectively, cannabis consumption has considerable immunomodulatory effects, and its use among cancer patients needs to be carefully considered due to its potential effects on the immune system, especially during treatment with immunotherapy.

59 citations


Authors

Showing all 2516 results

NameH-indexPapersCitations
Jorge E. Cortes1632784124154
James A. Russell124102487929
Barry M. Brenner12154065006
Razelle Kurzrock118112156594
Alan R. Saltiel9933649325
Michael Aviram9447931141
Jacob M. Rowe7532820043
Richard G. Wunderink7236826892
Doron Aronson6426113357
Nathan McDannold6420816293
Jacob I. Sznajder6127312201
Joseph Itskovitz-Eldor6021238298
Yehuda Chowers6021114526
Raanan Shamir6037919927
David Tanne6026441513
Network Information
Related Institutions (5)
Leiden University Medical Center
38K papers, 1.6M citations

90% related

Medical University of Vienna
37.4K papers, 1.3M citations

90% related

Boston Children's Hospital
215.5K papers, 6.8M citations

89% related

Mayo Clinic
169.5K papers, 8.1M citations

89% related

Cleveland Clinic
79.3K papers, 3.4M citations

88% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20236
202222
2021449
2020420
2019319
2018319